BioCentury

7:00 AM GMT, Jul 30, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Interference difference

Even though they are in line behind two other HIV compounds targeting chemokine receptor CCR5, Progenics Pharmaceuticals Inc. and Incyte Corp. each thinks its CCR5 inhibitor has advantages over the competition. Both companies presented data last week at the International AIDS Society meeting in Sydney.

Most HIV drugs are oral, but Progenics (PGNX, Tarrytown, N.Y.) believes PRO 140, a humanized antibody, could be developed as a first-in-class self-injectable for HIV patients.

CEO and CSO Paul Maddon, who worked on the research team that first identified CCR5's role in HIV infection in 1996, told BioCentury

Read the full 930 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.